IHS Chemical Week

Regions :: North Asia :: Korea

Lonza Signs Deal with LegoChem Biosciences to Provide Pre-clinical Material of Therapeutic Compound

3:59 AM MST | March 8, 2012 | Deepti Ramesh

Lonza says it has signed an agreement with biotech company LegoChem Biosciences (Daejeon, Korea), for the custom material production of a monoclonal antibody that will be used for in vivo proof of concept studies for their technology platform development. Lonza will produce pre-clinical material using its Light Path discovery services at its applied protein services facility at Cambridge, U.K., under the deal. Lonza’s Light Path discovery services “were specifically designed with the demands of pre-clinical assessment in mind,” says Janet White...

This information is only available to Chemical Week subscribers.


Forgot your user ID or password?
Click here to have it sent to you.

Not an IHS Chemical Week member yet?

Here's why you should be:

  • 31 issues of Chemical Week magazine in print or digital format
  • Critical daily news and analysis on chemweek.com
  • Free mobile edition 
  • 20+ years of online archives
  • Topical e-newsletters that capture the most impactful events
  • Special issues with a regional or company focus
  • Global Outlook issue

Subscribe now

100% Satisfaction Guarantee
If at any time you are not completely satisfied with IHS Chemical Week, simply notify us and we'll refund the balance of your paid subscription - no problem.

Learn more about group subscriptions and site licenses.


contact us | about us | customer care | privacy policy | sitemap | advertise

ihsCopyright © 2015 IHS, Inc. All rights reserved. Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa